A box of the Novavax Covid-19 vaccine displayed at a pharmacy in Schwenksville, Pennsylvania, U.S., Monday, August 1, 2022.
Bloomberg | Bloomberg | Getty Images
biotechnology company Novavax announced on Friday that its Covid-19 vaccine has been cleared for emergency use by the US Food and Drug Administration for adolescents aged 12 to 17.
In July, Novavax’s two-dose Covid-19 vaccine for adults 18 and older received emergency approval from the FDA.
Having more vaccine options for adults and children will “hopefully help increase vaccination rates, especially as we prepare for continued surges of Covid-19 with the onset of fall and back to school,” Stanley C. Erck, president and CEO of Novavax, said in a statement.
Novavax was an early entrant in the US government’s race to develop a Covid vaccine in 2020, receiving $1.8 billion in taxpayer funding from Operation Warp Speed. However, the small Maryland biotech company struggled to get manufacturing up and running quickly, and its clinical trial data read much later than its rivals. Pfizer Where Modern.
Dr. Peter Marks, a senior FDA official, said Novavax’s vaccine could potentially appeal to unvaccinated people who would prefer a vaccine that is not based on messenger RNA technology used by Pfizer and Moderna.
The Novavax vaccine is based on more conventional protein technology that has been used for decades in hepatitis B and HPV vaccines, while Pfizer and Moderna are the first FDA-approved vaccines to use mRNA.
Vaccines from Pfizer and Moderna use mRNA, a molecule encoded with genetic instructions, to tell human cells to produce copies of a viral particle called a spike protein. The immune system reacts to these copies of the spike, which prepares the human body to attack the actual virus.
Novavax makes copies of the virus spike outside of human cells. The spike’s genetic code is put into an insect virus that infects the moth’s cells, which produce copies that are then purified and extracted during the manufacturing process. The finished spike copies are injected into the human body, inducing an immune response against Covid.
The Novavax vaccine also uses an additional ingredient called an adjuvant, which is extracted and purified from the bark of a tree in South America, to induce a broader immune response. The injections consist of 5 micrograms of the peak copy and 50 micrograms of the adjuvant.
Two doses of the Novavax vaccine were 90% effective in preventing Covid disease across the board and 100% effective in preventing severe disease, according to clinical trial data in the United States and Mexico. However, the trial was conducted from December 2020 to September 2021, months before the omicron variant became mainstream.
Novavax presented no data on the vaccine’s effectiveness against the variant at the FDA committee meeting in June. However, the vaccine will likely have lower efficacy against omicron, as is the case with vaccines from Pfizer and Moderna. Omicron is so distinct from the original strain of Covid that antibodies produced by vaccines struggle to recognize and attack the variant.
Novavax released data in December showing that a third injection increased the immune response to levels comparable to the first two doses which were 90% effective against the disease. The company plans to ask the FDA to authorize a third dose of its vaccine.
The FDA clearance for Novavax’s vaccines comes as the United States prepares to update Covid vaccines to target the omicron BA.4 and BA.5 variants to increase protection against the virus. Novavax’s vaccine, like all other vaccines, is based on the original version of the virus that first appeared in Wuhan, China. The effectiveness of Covid vaccines against mild disease has declined significantly as the virus has evolved, although they still generally protect against severe disease.
Novavax presented data at a FDA committee meeting at the end of June demonstrating that a third dose of his vaccine produced a strong immune response against omicron and its subvariants. Committee members were impressed with the company’s data on omicron.
The Novavax vaccine also appears to carry a risk of heart inflammation in younger men, known as myocarditis and pericarditis, similar to Pfizer and Moderna injections. Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the outer lining of the heart.
FDA officials reported four cases of myocarditis and pericarditis during the Novavax clinical trial in young men between the ages of 16 and 28. People who develop heart inflammation as a side effect of Covid vaccines are usually hospitalized for several days as a precaution, but then recover.
The FDA has released an information sheet for health care providers warning that clinical trial data indicate there is an increased risk of myocarditis with the Novavax vaccine. According to the FDA, people who experience chest pain, shortness of breath, and a pounding or pounding sensation should seek medical attention immediately.
In the case of mRNA injections, the CDC found that the risk of myocarditis is higher from Covid infection than from vaccination. Myocarditis is usually caused by viral infections.
Denial of responsibility! newsnaveen.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – email@example.com. The content will be deleted within 24 hours.